Systemic Infiltration of FDA by Special Interests Undermines Rare Disease Treatments
Original framing: “Political influence ‘a serious problem’ for FDA under Trump, former commissioner says” — STAT News
The original framing omits the historical context of the FDA's regulatory capture, the role of industry lobbying in shaping policy, and the perspectives of marginalized communities who may be disproportionately affected by the lack of access to rare disease treatments.
Medium structural omission detected in mainstream coverage.
This narrative was produced by STAT News, a reputable healthcare publication, for an audience interested in healthcare policy and regulatory affairs. The framing serves to highlight the concerns of former FDA Commissioner Robert Califf, while obscuring the systemic issues within the FDA's structure and the broader power dynamics at play.
The FDA's regulatory capture is not a new phenomenon, dating back to the 1970s when the agency began to rely heavily on industry funding. This historical context is essential to understanding the current state of affairs and the need for systemic reforms.
The FDA's handling of rare disease treatments is a symptom of a broader problem within the agency's regulatory framework.